Modality
Peptide
MOA
WRNi
Target
WRN
Pathway
mTOR
Huntington's
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
Dec 2021
→ Mar 2026
Phase 1Current
NCT03180880
1,048 pts·Huntington's
2024-09→TBD·Terminated
NCT04112545
2,318 pts·Huntington's
2021-12→2026-03·Terminated
3,366 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-083w agoPh2 Data· Huntington's
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1/2
Termina…
P1/2
Termina…
Catalysts
Ph2 Data
2026-03-08 · 3w ago
Huntington's
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03180880 | Phase 1/2 | Huntington's | Terminated | 1048 | CfB |
| NCT04112545 | Phase 1/2 | Huntington's | Terminated | 2318 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 |